P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
Olalekan Oluwole,
Markqayne Ray,
Neil Davies,
Rory Bradford,
Calum Jones,
Anik Patel,
Frederick Locke
Affiliations
Olalekan Oluwole
1 Vanderbilt University Medical Center, Nashville, United States
Markqayne Ray
2 Kite, A Gilead Company, Santa Monica, United States
Neil Davies
3 Mtech Access, Cheadle Hulme, United Kingdom
Rory Bradford
3 Mtech Access, Cheadle Hulme, United Kingdom
Calum Jones
3 Mtech Access, Cheadle Hulme, United Kingdom
Anik Patel
2 Kite, A Gilead Company, Santa Monica, United States
Frederick Locke
4 H Lee Moffitt Cancer Center, Tampa, United States
